| ABSTRACT Objective: To conduct long term economic evaluation for the major adverse events of insulin glargine and liraglutide, to provide reference for drug selection in patients with type 2 diabetes, so as to improve the quality of life of patients with diabetes within a sustainable economic level. Methods:The Markov model was established according to the major adverse events of the study drug, and transfer probability between states, state costs and utility values were collected. The model was analyzed by the TreeAge Pro 2011 software for roll back analysis, half cycle correction and sensitivity analysis, and calculate Incremental cost effectiveness ratio (ICER). Results:The average costs of insulin glargine, liraglutide 1.2 mg and liraglutide 1.8 mg for 20 years were 70 948.70, 93 939.31 and 138 108.92 yuan, respectively, and 5.14, 6.84 and 7.16 quality adjusted life years (QALYs) were obtained. Compared with insulin glargine, the incremental cost effectiveness ratio (ICER) of liraglutide 1.2 mg and liraglutide 1.8 mg was 13 523.89 and 33 247.63, respectively. Conclusion:Compared with insulin glargine, both liraglutide interventions have a cost effective advantage, and liraglutide 1.2 mg is more economical. |
